TYK2 and type 1 diabetes mellitus: These observations suggest that early intervention with a TYK2 inhibitor may be a potent immunotherapeutic strategy for autoimmune T1D, and treatment with the inhibitor in the late stage of T1D may also be effective at suppressing the autoimmune process.